Kinemed Receives U.S. Patent Allowance for Noscapine for ALS

Kinemed, Inc. has received a notice of allowance from the U.S. Patent and Trademark Office for their patent covering noscapine for treatment of ALS, PD and diabetic neuropathy. This important step in securing patent protection for a new use of this approved drug is essential for Kinemed in order to de-risk the drug candidate and advance its development for ALS. Research from the company has shown that noscapine normalizes microtubule breakdown and impaired transport of cargo proteins, processes which are linked to several neurodegenerative diseases, including ALS. In addition, the company has developed a proprietary in-vivo technique to track protein transport in both humans and animal models, which holds promise as a diagnostic tool that could also advance the identification and development of other ALS drugs.

Kinemed, Inc. has received a notice of allowance from the U.S. Patent and Trademark Office for their patent covering noscapine for treatment of ALS, PD and diabetic neuropathy. This important step in securing patent protection for a new use of this approved drug is essential for Kinemed in order to de-risk the drug candidate and advance its development for ALS. Research from the company has shown that noscapine normalizes microtubule breakdown and impaired transport of cargo proteins, processes which are linked to several neurodegenerative diseases, including ALS. In addition, the company has developed a proprietary in-vivo technique to track protein transport in both humans and animal models, which holds promise as a diagnostic tool that could also advance the identification and development of other ALS drugs.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail